Wells Fargo
KPTI icon

Wells Fargo’s Karyopharm Therapeutics KPTI Stock Holding History

Wells Fargo’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44
Closed -$450 – 7153
2024
Q4 		$450 Hold
44
– – ﹤0.01% 6318
2024
Q3 		$553 Buy
44
+43
+4,300% +$534 ﹤0.01% 6163
2024
Q2 		$12 Sell
1
-2,259
-100% -$37.4K ﹤0.01% 6612
2024
Q1 		$51.2K Buy
2,260
+302
+15% +$5.29K ﹤0.01% 5244
2023
Q4 		$25.4K Buy
1,958
+446
+29% +$6.01K ﹤0.01% 5545
2023
Q3 		$30.4K Sell
1,512
-1,636
-52% -$36.7K ﹤0.01% 5427
2023
Q2 		$84.5K Sell
3,148
-8,028
-72% -$346K ﹤0.01% 5141
2023
Q1 		$652K Buy
11,176
+11,168
+139,600% +$551K ﹤0.01% 3668
2022
Q4 		$415 Sell
8
-369
-98% -$25.6K ﹤0.01% 6433
2022
Q3 		$30K Sell
377
-80
-18% -$5.97K ﹤0.01% 5190
2022
Q2 		$31K Sell
457
-2,268
-83% -$208K ﹤0.01% 5252
2022
Q1 		$302K Sell
2,725
-1,666
-38% -$208K ﹤0.01% 4744
2021
Q4 		$424K Buy
4,391
+2,698
+159% +$269K ﹤0.01% 4792
2021
Q3 		$148K Sell
1,693
-351
-17% -$36.4K ﹤0.01% 5221
2021
Q2 		$316K Sell
2,044
-4,928
-71% -$715K ﹤0.01% 4847
2021
Q1 		$1.1M Sell
6,972
-3,763
-35% -$793K ﹤0.01% 4175
2020
Q4 		$2.49M Sell
10,735
-1,199
-10% -$278K ﹤0.01% 3328
2020
Q3 		$2.61M Sell
11,934
-119
-1% -$29.1K ﹤0.01% 3091
2020
Q2 		$3.42M Buy
12,053
+7,826
+185% +$2.31M ﹤0.01% 2818
2020
Q1 		$1.22M Buy
4,227
+132
+3% +$36.4K ﹤0.01% 3405
2019
Q4 		$1.18M Buy
4,095
+140
+4% +$30.4K ﹤0.01% 3745
2019
Q3 		$571K Sell
3,955
-71
-2% -$9.63K ﹤0.01% 4279
2019
Q2 		$361K Buy
4,026
+318
+9% +$25.5K ﹤0.01% 4605
2019
Q1 		$325K Buy
3,708
+673
+22% +$74.6K ﹤0.01% 4581
2018
Q4 		$426K Buy
3,035
+217
+8% +$36.6K ﹤0.01% 4431
2018
Q3 		$720K Buy
2,818
+349
+14% +$96.5K ﹤0.01% 4191
2018
Q2 		$629K Buy
2,469
+67
+3% +$16.6K ﹤0.01% 4293
2018
Q1 		$483K Buy
2,402
+337
+16% +$67.2K ﹤0.01% 4408
2017
Q4 		$298K Buy
2,065
+327
+19% +$52.5K ﹤0.01% 4753
2017
Q3 		$285K Buy
1,738
+168
+11% +$24.1K ﹤0.01% 4709
2017
Q2 		$213K Sell
1,570
-1,337
-46% -$198K ﹤0.01% 4743
2017
Q1 		$560K Buy
2,907
+1,552
+115% +$249K ﹤0.01% 4166
2016
Q4 		$191K Buy
1,355
+469
+53% +$63.4K ﹤0.01% 4805
2016
Q3 		$129K Sell
886
-27
-3% -$3.25K ﹤0.01% 4753
2016
Q2 		$91K Sell
913
-98
-10% -$12.7K ﹤0.01% 4891
2016
Q1 		$134K Sell
1,011
-7,981
-89% -$881K ﹤0.01% 4647
2015
Q4 		$1.79M Buy
8,992
+8,263
+1,133% +$1.79M ﹤0.01% 3064
2015
Q3 		$115K Buy
729
+29
+4% +$7.76K ﹤0.01% 4788
2015
Q2 		$286K Buy
700
+436
+165% +$188K ﹤0.01% 4402
2015
Q1 		$122K Buy
264
+222
+529% +$95.7K ﹤0.01% 4665
2014
Q4 		$24K Hold
42
– – ﹤0.01% 5280
2014
Q3 		$22K Sell
42
-17
-29% -$9.59K ﹤0.01% 5253
2014
Q2 		$41K Buy
+59
New +$27.5K ﹤0.01% 5048

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wells Fargo's KPTI Position: Q1 2025 in Review

Wells Fargo sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 44 shares — an estimated $450 sold.

Wells Fargo first reported a position in KPTI in Q2 2014 and held it in 43 quarters. The position peaked at $3.42M in Q2 2020. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Wells Fargo reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wells Fargo sold 44 Karyopharm Therapeutics shares in Q1 2025, an estimated $450.
  • Wells Fargo first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 43 quarters.
  • Wells Fargo's Karyopharm Therapeutics position peaked at $3.42M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.